You are here: Industry Insights > prostate

News List

AUA: Atenolol Linked to Drop in Low-, Intermediate-Risk Prostate Cancer drugs
May 06, 2019
Atenolol is associated with a reduction in incident intermediate- and low-risk prostate cancer (PCa)...
Does Hormone Therapy for Prostate Cancer Raise Dementia Risk? drugs
May 06, 2019
Does Hormone Therapy for Prostate Cancer Raise Dementia Risk?
MDxHealth's SelectMDx Test Successfully Stratifies Men Who May Benefit from mp-MRI for Prostate Cancer Diagnosis b3cnewswire
April 23, 2019
MDxHealth's SelectMDx Test Successfully Stratifies Men Who May Benefit from mp-MRI for Prostate Cancer Diagnosis.
Immunotherapy drug could boost hormone treatment for prostate cancer europeanpharmaceuticalreview
April 22, 2019
Researchers believe the combination with established treatment could improve outcomes in prostate cancer…
Prostate cancer treatment reduced from 37 treatments to 5 europeanpharmaceuticalreview
April 22, 2019
A minimally invasive hydrogel technology was administered, and has previously shown to decrease treatment side effects…
Darolutamide NDA to treat non-metastatic castration-resistant prostate cancer europeanpharmaceuticalreview
April 12, 2019
A New Drug Application has been made to the US Food and Drug Administration for the drug darolutamide to treat non-metastatic prostate cancer…
Barriers to Prostate Cancer Research in Black Men Identified drugs
November 01, 2018
Barriers to Prostate Cancer Research in Black Men Identified
Study discovers immunotherapy could treat some aggressive prostate cancers pharmatimes
September 14, 2018
New research has discovered a subset of men with prostate cancer who have specific faults in their tumours that significantly worsen their chances...
Blood test predicts treatment response for metastatic prostate cancer europeanpharmaceuticalreview
July 03, 2018
Testing could lead to extension of life through improved clinical decision-making by identifying patients who need to switch from targeted hormonal therapy to chemotherapy…
Potential drug candidates halt prostate and breast cancer growth worldpharmanews
March 10, 2017
Scientists on the Florida campus of The Scripps Research Institute (TSRI) have designed two new drug candidates to target prostate and triple negative breast cancers.

Previous page 1 2 3 Next page